Survey
Quarterly Survey: mCRPC and Pluvico Lutetium-177 PSMA Therapy October 2025
Ticker(s): NVSSurvey results include 20 Oncologists.
How many patients with Advanced Metastatic Prostate Cancer are in your practice?
How would you best describe your practice?
- Academic
- Community
- Other
How many of your patients do you consider eligible for Pluvicto (Lutetium-177 vipivotide tetraxetan)?
How many of your patients do you prescribe Pluvicto today?
How many of your patients started Pluvicto in the last 30 days?
How many of your patients discontinued Pluvicto in the last 30 days?
How many total patients do you expect to be on Pluvicto in the next 30 days (cumulative)?
How do you expect usage of Pluvicto in your patients to change moving forward?
- Increase:
- Stay the same:
- Decrease:
In response to your answer above: why is that?
Do you have any concerns regarding the safety profile of Pluvicto?
Have you had any recent experience or issues with availability/supply chain of Pluvicto? If so, has your access increased over time?
How would you rate Pluvicto on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Payor Access
How does Pluvicto compare to the standard of care in the second line setting (taxane- naive) in your practice? Please be specific.
What is your opinion of alpha emitters as opposed to the beta emitters?
How do you view the potential of radioligand therapies compared to antibody drug conjugates?
Lastly, what do you think about the potential of actinium-based compounds for radioligand therapies as opposed to lutetium?
What proportion (%) of patients do you expect to receive it in 2L taxane-naive mCRPC?
Based on the results of PSMA Addition (Pluvicto + Standard of care ADT + ARPI in mHSPC), what is your expected use of Pluvicto in mHSPC patients?
What is a clinically meaningful difference in PFS and Overall survival for this population?
What is your opinion of alpha emitters as opposed to the beta emitters?
How do you view the potential of radioligand therapies compared to antibody drug conjugates?
Lastly, what do you think about the potential of actinium-based compounds for radioligand therapies as opposed to lutetium?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
